Q-omics provides the consensus-scored TPRG1L profile across patient tissues and cancer cell-line models. TPRG1L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TPRG1L is differentially expressed in 15, with the highest sampling consensus in KIRP. Additionally, TPRG1L protein abundance shows 27,420 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where TPRG1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPRG1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPRG1L survival associations across molecular data types. TPRG1L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPRG1L RNA expression–survival associations across cancer types. High TPRG1L expression shows unfavorable associations in ACC and PAAD, but favorable associations in KIRC, UVM, MESO and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TPRG1L RNA expression.
This table summarizes TPRG1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TPRG1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPRG1L shows lower tumor expression in KIRP, KICH, BLCA, LUAD, COAD and KIRC. The KIRP box plot shows higher TPRG1L RNA expression in normal versus tumor tissue (log2 FC = −1.448, t-test p < 0.001).
This table shows molecular features associated with TPRG1L in patient tissues and cancer cell lines. In patient samples, TPRG1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPRG1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
